Relief Therapeut Stock Price, News & Analysis

Relief Therapeutics S/ADR (RLFTY) represents an interest in RELIEF THERAPEUTICS Holding SA, a commercial-stage biopharmaceutical company. According to company disclosures, Relief focuses on delivering treatment options for select specialty, unmet and rare diseases, with particular emphasis on rare dermatological, metabolic and respiratory conditions. The company highlights core expertise in drug delivery systems and drug repurposing, and notes that it has brought several approved products to market through licensing and distribution partnerships.

Relief states that it is headquartered in Geneva, Switzerland, and that its ordinary shares are listed on the SIX Swiss Exchange under the symbol RLF. In the United States, the company indicates that it is quoted on the OTCQB market under the symbols RLFTF and RLFTY. These cross-listings allow investors to access the company both on the Swiss market and through U.S. over-the-counter trading.

Business focus and therapeutic areas

Based on multiple company announcements, Relief positions itself as a biopharmaceutical company dedicated to advancing treatment paradigms for rare and debilitating diseases. Its clinical pipeline is described as including treatments designed to address critical unmet medical needs in rare dermatological, metabolic and respiratory conditions. Relief also reports experience in drug delivery systems and drug repurposing, which it presents as core capabilities supporting its development programs.

The company has publicly discussed several investigational and pipeline assets. RLF‑TD011 is described as a highly pure, stabilized hypochlorous acid solution developed using Relief's proprietary TEHCLO™ technology. It is characterized as a sprayable, self-administered solution for targeted wound application, with strong antimicrobial properties and the goal of efficiently controlling infection and inflammation in epidermolysis bullosa (EB), a rare genetic skin disorder. Relief notes that RLF‑TD011 has received both Orphan Drug and Rare Pediatric Disease designations from the U.S. Food and Drug Administration (FDA) for EB.

Another program highlighted by Relief is RLF‑OD032, which the company describes as an innovative, ready-to-use, portable and highly concentrated liquid suspension formulation of sapropterin dihydrochloride for oral administration in phenylketonuria (PKU). Relief reports that RLF‑OD032 is designed to lower blood phenylalanine levels in adult and pediatric PKU patients and to reduce the volume of medication required compared to existing sapropterin formulations. The company has announced positive results from a pivotal bioequivalence study in which RLF‑OD032 demonstrated bioequivalence to KUVAN Powder, the reference listed drug, under FDA criteria.

Pipeline characteristics and regulatory designations

Relief emphasizes that its pipeline targets rare and debilitating diseases where existing treatment options are limited. For RLF‑TD011, the company reports prior clinical experience in non-EB wounds and investigator-initiated data in EB patients, along with regulatory designations that may provide incentives such as market exclusivity if approval is obtained. For RLF‑OD032, Relief has described a development path using the U.S. 505(b)(2) regulatory pathway, supported by bioequivalence data relative to an existing reference product.

Across its programs, Relief highlights the use of proprietary technology (such as TEHCLO for hypochlorous acid solutions) and a focus on formulations and approaches intended to improve patient experience and adherence, particularly in pediatric and rare-disease settings. The company also notes that it has successfully commercialized products through licensing and distribution partnerships, although specific products and partners are not detailed in the provided information.

Corporate developments and combination with NeuroX

In a series of announcements, Relief described plans to combine with NeuroX Group SA, a Swiss-based commercial-stage company that acquired strategic assets and the MindMaze brand. NeuroX is characterized as operating a brain health platform delivering digital neurotherapeutics for neurological diseases and brain disorders, based on an advanced brain technology platform integrating software, sensors and telehealth. MindMaze neurotherapeutics are described as clinically validated and deployed across clinics and home settings, with applications in conditions such as stroke, Parkinson's disease and at-risk aging, and an R&D pipeline extending to multiple sclerosis, spinal cord injury, traumatic brain injury and Alzheimer's disease.

Relief first announced a binding term sheet for a proposed business combination with NeuroX, with the stated objective of creating a publicly listed, AI-based therapeutics platform integrating software-delivered neurotherapeutics with pharmacological treatments. Subsequently, shareholders of Relief approved resolutions authorizing the business combination and the renaming of the company to MindMaze Therapeutics Holding SA upon completion. A later announcement confirmed that the business combination with NeuroX was completed and that the combined entity operates under the name MindMaze Therapeutics Holding SA.

Following completion of the transaction, the company describes itself as MindMaze Therapeutics, a Swiss-based, commercial-stage company formed in December 2025 through the business combination of RELIEF THERAPEUTICS Holding SA and NeuroX Group SA. MindMaze Therapeutics states that it develops and commercializes digital treatments for neurological diseases and brain disorders, built on an advanced brain technology platform integrating software, sensors and telehealth. It also reports that it manages Relief's preexisting portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic and respiratory diseases.

Listing status and ticker information

According to the business combination announcements, the combined company is listed on the SIX Swiss Exchange under the ticker MMTX. The same disclosures state that MindMaze Therapeutics is quoted in the United States on the OTCQB market under the symbols RLFTF and RLFTY. This indicates that the RLFTY symbol now corresponds to MindMaze Therapeutics Holding SA, which incorporates the historical Relief Therapeutics business and the NeuroX/MindMaze digital neurotherapeutics platform.

Position within healthcare and neurology

Based on the company's own descriptions, the combined entity brings together a portfolio of digital neurotherapeutics for neurological diseases and a set of biopharmaceutical assets for rare dermatological, metabolic and respiratory conditions. MindMaze neurotherapeutics are characterized as disease-modifying motor and cognitive treatments delivered via software and hardware, supported by clinical studies, regulatory clearances and reimbursement pathways, including a CMS Category III reimbursement code in the United States for home-based digital neurorehabilitation. Relief's historical assets add a pipeline of drug candidates such as RLF‑TD011 and RLF‑OD032, which target rare diseases with significant unmet medical need.

The company presents this combined platform as a way to address neurological and rare disease care across settings ranging from hospitals and rehabilitation centers to patients' homes, while also maintaining a focus on rare dermatological, metabolic and respiratory indications. All of these characterizations are drawn from company-issued news releases and represent how the company describes its own activities and strategy.

Investor considerations

Investors researching RLFTY are reviewing an OTCQB-quoted instrument that, according to company statements, now reflects MindMaze Therapeutics Holding SA, formed through the combination of Relief Therapeutics and NeuroX. The company emphasizes its commercial-stage status, its digital neurotherapeutics platform, and its rare-disease biopharmaceutical pipeline. As with any biopharmaceutical and health technology investment, outcomes depend on factors such as clinical trial results, regulatory decisions, reimbursement developments and the execution of the combined company's strategy, all of which are subject to uncertainty and are not detailed beyond the information contained in the cited company communications.